Patents by Inventor Ronald Farquhar

Ronald Farquhar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B INFECTION
    Publication number: 20240150412
    Abstract: Disclosed herein are compositions and methods for the treatment of hepatitis B infection, including chronic hepatitis B (CHB).
    Type: Application
    Filed: August 21, 2023
    Publication date: May 9, 2024
    Applicants: CLEARB THERAPEUTICS LTD., MELBOURNE HEALTH
    Inventors: Renae Walsh, Stephen Locarnini, Hans Netter, Ronald Farquhar
  • Methods and compositions for the treatment of C. difficile
    Patent number: 11896628
    Abstract: Disclosed herein are compositions and methods for preventing, ameliorating, or treating Clostridium difficile infections and/or reducing the severity of one or more risk factors, signs, or symptoms associated with C. difficile infections. In particular, the technology of the present disclosure relates to methods for administering an effective amount of a composition comprising strains of Bacillus amyloliquefaciens bacteria identified as ART24, ART4, and ART 12, to a subject suffering from or at risk for C. difficile infections.
    Type: Grant
    Filed: July 1, 2022
    Date of Patent: February 13, 2024
    Assignee: Artugen Therapeutics Ltd.
    Inventors: Ronald Farquhar, Christopher K. Murphy, Colin Hill, Paul Ross, Mary Rea, Michelle O'Donnell, Brian Healy, Laurent Chesnel
  • Methods and compositions for the treatment of hepatitis B infection
    Patent number: 11773141
    Abstract: Disclosed herein are compositions and methods for the treatment of hepatitis B infection, including chronic hepatitis B (CHB).
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: October 3, 2023
    Assignees: CLEARB THERAPEUTICS LTD., MELBOURNE HEALTH
    Inventors: Renae Walsh, Stephen Locarnini, Hans Netter, Ronald Farquhar
  • PROBENECID COMPOUNDS FOR THE TREATMENT OF INFLAMMASOME-MEDIATED LUNG DISEASE
    Publication number: 20230257357
    Abstract: Disclosed herein are methods, compounds, and compositions for treating or preventing inflammasome-mediated diseases or conditions, including inflammasome-mediated lung diseases or conditions.
    Type: Application
    Filed: June 24, 2021
    Publication date: August 17, 2023
    Applicant: Bacainn Biotherapeutics, Ltd.
    Inventors: Chris Murphy, Ronald Farquhar, Roland E. Dolle, Manuel Navia
  • CYCLOSPORINE COMPOSITIONS AND METHODS OF USE
    Publication number: 20230192771
    Abstract: Disclosed herein are cyclosporine compounds and methods for use in the treatment or prevention of neutrophil-mediated inflammation, wherein the compounds inhibit the activity of MRP2 and FPRL
    Type: Application
    Filed: August 19, 2022
    Publication date: June 22, 2023
    Applicant: Bacainn Biotherapeutics, Ltd.
    Inventors: Chris Murphy, Ronald Farquhar, Roland E. Dolle
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF C. DIFFICILE
    Publication number: 20230132133
    Abstract: Disclosed herein are compositions and methods for preventing, ameliorating, or treating Clostridium difficile infections and/or reducing the severity of one or more risk factors, signs, or symptoms associated with C. difficile infections. In particular, the technology of the present disclosure relates to methods for administering an effective amount of a composition comprising strains of Bacillus amyloliquefaciens bacteria identified as ART24, ART4, and ART 12, to a subject suffering from or at risk for C. difficile infections.
    Type: Application
    Filed: July 1, 2022
    Publication date: April 27, 2023
    Applicant: Artugen Therapeutics Ltd.
    Inventors: Ronald Farquhar, Christopher K. Murphy, Colin Hill, Paul Ross, Mary Rea, Michelle O'Donnell, Brian Healy, Laurent Chesnel
  • Methods and compositions for the treatment of C. difficile
    Patent number: 11419900
    Abstract: Disclosed herein are compositions and methods for preventing, ameliorating, or treating Clostridium difficile infections and/or reducing the severity of one or more risk factors, signs, or symptoms associated with C. difficile infections. In particular, the technology of the present disclosure relates to methods for administering an effective amount of a composition comprising strains of Bacillus amyloliquefaciens bacteria identified as ART24, ART4, and ART 12, to a subject suffering from or at risk for C. difficile infections.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: August 23, 2022
    Assignee: Artugen Therapeutics Ltd.
    Inventors: Ronald Farquhar, Christopher K. Murphy, Colin Hill, Paul Ross, Mary Rea, Michelle O'Donnell, Brian Healy, Laurent Chesnel
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B INFECTION
    Publication number: 20220002349
    Abstract: Disclosed herein are compositions and methods for the treatment of hepatitis B infection, including chronic hepatitis B (CHB).
    Type: Application
    Filed: May 9, 2019
    Publication date: January 6, 2022
    Inventors: Renae Walsh, Stephen Locarnini, Hans Netter, Ronald Farquhar
  • CYCLOSPORINE COMPOSITIONS AND METHODS OF USE
    Publication number: 20210277064
    Abstract: Disclosed herein are cyclosporine compounds and methods for use in the treatment or prevention of neutrophil-mediated inflammation, wherein the compounds inhibit the activity of MRP2 and FPR1.
    Type: Application
    Filed: August 20, 2019
    Publication date: September 9, 2021
    Inventors: Chris Murphy, Ronald Farquhar, Roland E. Dolle
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF C. DIFFICILE
    Publication number: 20210220411
    Abstract: Disclosed herein are compositions and methods for preventing, ameliorating, or treating Clostridium difficile infections and/or reducing the severity of one or more risk factors, signs, or symptoms associated with C. difficile infections. In particular, the technology of the present disclosure relates to methods for administering an effective amount of a composition comprising strains of Bacillus amyloliquefaciens bacteria identified as ART24, ART4, and ART 12, to a subject suffering from or at risk for C. difficile infections.
    Type: Application
    Filed: June 6, 2019
    Publication date: July 22, 2021
    Inventors: Ronald Farquhar, Christopher K. Murphy, Colin Hill, Paul Ross, Mary Rea, Michelle O'Donnell, Brian Healy, Laurent Chesnel